Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

The development of RAPTA compounds for the treatment of tumors

(2016) Benjamin S. Murray et al.   COORDINATION CHEMISTRY REVIEWS

Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A

(2016) Chiara Pelillo et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

(2015) Andrea Weiss et al.   ANGIOGENESIS

Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process

(2015) L. Brescacin et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo

(2015) Jasmine G. Lee et al.   NEOPLASIA

The chicken chorioallantoic membrane model in biology, medicine and bioengineering

(2014) Patrycja Nowak-Sliwinska et al.   ANGIOGENESIS

Cytokinesis Failure Triggers Hippo Tumor Suppressor Pathway Activation

(2014) Neil J. Ganem et al.   CELL

Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer

(2014) Alberta Bergamo et al.   INVESTIGATIONAL NEW DRUGS

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

(2014) Suzanne Leijen et al.   INVESTIGATIONAL NEW DRUGS

In vivo anti-tumor activity of the organometallic ruthenium(ii)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas

(2014) Andrea Weiss et al.   Chemical Science

Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

(2014) Zenita Adhireksan et al.   Nature Communications

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo

(2013) Petra Heffeter et al.   EUROPEAN JOURNAL OF CANCER

Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters

(2013) Alexey A. Nazarov et al.   Scientific Reports

Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells

(2012) Tsuyoshi Ohta et al.   CANCER BIOLOGY & THERAPY

Designing organometallic compounds for catalysis and therapy

(2012) Anna Louisa Noffke et al.   CHEMICAL COMMUNICATIONS

Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients

(2012) A. W. Griffioen et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

(2012) Samir E. Witta et al.   JOURNAL OF CLINICAL ONCOLOGY

The possible role of chemotherapy in antiangiogenic drug resistance

(2012) Guido Bocci et al.   MEDICAL HYPOTHESES

Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion

(2011) Patrycja Nowak-Sliwinska et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology?

(2011) Anne Q. Reuwer et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Approaching tumour therapy beyond platinum drugs

(2011) A. Bergamo et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity

(2011) Patrycja Nowak-Sliwinska et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

(2010) Petra Heffeter et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways

(2010) F. Yang et al.   MOLECULAR CANCER RESEARCH

The Neovessel Occlusion Efficacy of 151-Hydroxypurpurin-7-Lactone Dimethyl Ester Induced with Photodynamic Therapy

(2010) Siang Hui Lim et al.   PHOTOCHEMISTRY AND PHOTOBIOLOGY

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

(2009) Frederike Lentz et al.   ANTI-CANCER DRUGS

Aurora B-Mediated Abscission Checkpoint Protects against Tetraploidization

(2009) Patrick Steigemann et al.   CELL

In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model

(2009) A. Bergamo et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model

(2009) Patrycja Nowak-Sliwinska et al.   MICROVASCULAR RESEARCH

Bioorganometallic chemistry—from teaching paradigms to medicinal applications

(2008) Christian G. Hartinger et al.   CHEMICAL SOCIETY REVIEWS

KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

(2008) Christian G. Hartinger et al.   CHEMISTRY & BIODIVERSITY

Classification of chromosome segregation errors in cancer

(2008) David Gisselsson   CHROMOSOMA

The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

(2008) Soumya Chatterjee et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Antitumour metal compounds: more than theme and variations

(2007) Michael A. Jakupec et al.   DALTON TRANSACTIONS